NCT01216176 2025-01-08
A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer
University of Miami
Phase 1/2 Completed
Clinical Trials
13 trialsNCT00752206 2020-01-18
A Placebo-Controlled Study of Saracatinib (AZD0530) in Patients With Recurrent Osteosarcoma Localized to the Lung
Sarcoma Alliance for Research through Collaboration
Phase 2 Terminated
NCT00397878 2019-08-20
AZD0530 (NSC 735464) in Treating Patients With Previously Treated Metastatic Colon Cancer or Rectal Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00735917 2019-04-02
Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00638937 2018-08-29
AZD0530 to Treat Recurrent Stage IIIB/IV NSCLC Previously Treated With Combination Chemotherapy
National Cancer Institute (NCI)
Phase 2 Completed
NCT00659360 2018-06-29
AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00513071 2018-04-19
AZD0530 in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
National Cancer Institute (NCI)
Phase 2 Completed
NCT00718809 2015-06-10
Saracatinib in Treating Patients With Relapsed or Refractory Thymoma or Thymic Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT01196741 2015-05-05
SaPPrOC
University College, London
Phase 2/3 Completed
NCT01267266 2015-04-01
Saracatinib in Treating Patients With Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00669019 2014-05-21
Saracatinib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT00513435 2014-04-30
Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00559507 2014-04-30
Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 2 Completed